| The science and business of genetic ancestry testing DA Bolnick, D Fullwiley, T Duster, RS Cooper, JH Fujimura, J Kahn, ... Science 318 (5849), 399-400, 2007 | 352 | 2007 |
| How a drug becomes ethnic: law, commerce, and the production of racial categories in medicine J Kahn Yale J. Health Pol'y L. & Ethics 4, 1, 2004 | 323 | 2004 |
| Race in a bottle: The story of BiDil and racialized medicine in a post-genomic age J Kahn Columbia University Press, 2012 | 258 | 2012 |
| Budgeting democracy: State building and citizenship in America, 1890-1928 J Kahn (No Title), 1997 | 197 | 1997 |
| Race and ancestry in biomedical research: exploring the challenges T Caulfield, SM Fullerton, SE Ali-Khan, L Arbour, EG Burchard, ... Genome medicine 1, 1-8, 2009 | 155 | 2009 |
| BiDil: Race Medicine Or Race Marketing? Using race to gain a commercial advantage does not advance the goal of eliminating racial/ethnic disparities in health care. P Sankar, J Kahn Health Affairs 24 (Suppl1), W5-455-W5-464, 2005 | 147 | 2005 |
| Bringing Dignity Back to Light: Publicity Rights and the Eclipse of the Tort of Appropriation of Identity J Kahn Cardozo Arts & Ent. LJ 17, 213, 1999 | 103 | 1999 |
| Privacy as a legal principle of identity maintenance J Kahn Seton Hall. L. Rev. 33, 371, 2002 | 101 | 2002 |
| Race on the brain: What implicit bias gets wrong about the struggle for racial justice J Kahn Columbia University Press, 2017 | 96 | 2017 |
| Getting the numbers right: statistical mischief and racial profiling in heart failure research J Kahn Health Psychology, 451-460, 2016 | 79 | 2016 |
| The OHRP and SUPPORT—another view R Macklin, L Shepherd, A Dreger, A Asch, F Baylis, H Brody, LR Churchill, ... New England Journal of Medicine 369 (2), e3, 2013 | 75 | 2013 |
| Exploiting race in drug development: BiDil's interim model of pharmacogenomics J Kahn Social Studies of Science 38 (5), 737-758, 2008 | 73 | 2008 |
| Race in a bottle J Kahn Scientific American 297 (2), 40-45, 2007 | 71 | 2007 |
| From disparity to difference: How race-specific medicines may undermine policies to address inequalities in health care J Kahn S. Cal. Interdisc. LJ 15, 105, 2005 | 70 | 2005 |
| Genes, race, and population: avoiding a collision of categories J Kahn American Journal of Public Health 96 (11), 1965-1970, 2006 | 67 | 2006 |
| Misreading race and genomics after BiDil J Kahn Nature Genetics 37 (7), 655-656, 2005 | 65 | 2005 |
| Race-ing patents/patenting race: an emerging political geography of intellectual property in biotechnology J Kahn Iowa L. Rev. 92, 353, 2006 | 62 | 2006 |
| Mapping" race": Critical approaches to health disparities research RB Valdez, J Kahn, JL Graves Jr, JS Kaufman, JA Garcia, SJC Lee, ... Rutgers University Press, 2013 | 58 | 2013 |
| Flaws in the US Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients GTH Ellison, JS Kaufman, RF Head, PA Martin, JD Kahn Journal of Law, Medicine & Ethics 36 (3), 449-457, 2008 | 44 | 2008 |
| Race, genes, and justice: A call to reform the presentation of forensic DNA evidence in criminal trials J Kahn Brooklyn law review 74 (2), 325, 2008 | 42 | 2008 |
